Penetration of ciprofloxacin and metabolites into human lung, bronchial and pleural tissue after 250 and 500 mg oral ciprofloxacin
- PMID: 1790720
- DOI: 10.1159/000238860
Penetration of ciprofloxacin and metabolites into human lung, bronchial and pleural tissue after 250 and 500 mg oral ciprofloxacin
Abstract
Ciprofloxacin (CIP) and metabolite concentrations in lung tissue, parietal pleura and bronchial tissue were assessed in 43 adult patients who underwent lung surgery. A single oral dose of CIP was given for prophylaxis of bacterial infections. Two to 6 h prior to tissues sampling, 23 patients received 250 mg and 20 subjects 500 mg of the substance. Blood plasma samples were obtained at the same time as the lung tissue samples. CIP and its metabolites were assayed chemically by high-pressure liquid chromatography (HPLC). After 250 mg CIP, the individual lung tissue CIP concentrations during the 2- to 6-hour post-dose period ranged from 0.5 to 4.8 mg/kg. In 20 of the 23 lung samples, the CIP concentrations were above 1 mg/kg. After 500 mg CIP, the corresponding lung CIP concentrations ranged from 1.6 to 6.0 mg/kg. The CIP lung concentrations were, irrespective of the dose size, between 2 and 7 times higher than the simultaneous blood plasma concentrations. This indicates an excellent penetration of CIP and its metabolites into lung tissue. Bronchial tissue was obtained in 9 cases. Penetration into bronchial mucosa tissue was good as well, as indicated by tissue/plasma ratio values between 1.5 and 4.4. Individual CIP concentrations in the patients given 250 mg CIP, ranged from 1.0 to 1.6 mg/kg. In the patients who received 500 mg, the range was from 1.7 to 3.4 mg/kg. Tissue/plasma ratio values between 0.8 and 2.1 indicated that penetration to pleural tissues was good as well. Metabolite concentrations in all of the tissues assayed (lung, bronchial mucosa, pleural tissue) were low when compared to the concentrations of CIP. The concentrations in lung, pleural and bronchial tissue will probably permit low doses in the treatment of most respiratory tract infections. The broad spectrum of antibacterial activity, the good tissue penetration, chemical stability and the good safety record of the substance means that the drug is potentially a useful agent for perioperative antibiotic prophylaxis.
Similar articles
-
The penetration of ciprofloxacin into bronchial mucosa, lung parenchyma, and pleural tissue after intravenous administration.Eur J Clin Pharmacol. 1993;44(1):101-2. doi: 10.1007/BF00315290. Eur J Clin Pharmacol. 1993. PMID: 8436147
-
The distribution of ciprofloxacin and its metabolites in human plasma, pulmonary and bronchial tissues.Int J Clin Pharmacol Ther Toxicol. 1991 Sep;29(9):352-6. Int J Clin Pharmacol Ther Toxicol. 1991. PMID: 1937996 Clinical Trial.
-
Pharmacokinetics of cefonicid in serum and its penetration into lung tissue, bronchial mucosa and pleura.Int J Clin Pharmacol Res. 1989;9(1):49-53. Int J Clin Pharmacol Res. 1989. PMID: 2707925
-
Penetration of ciprofloxacin into gynecologic tissues.Am J Med. 1987 Apr 27;82(4A):133-8. Am J Med. 1987. PMID: 3555027 Review.
-
Ofloxacin concentrations in tissues involved in respiratory tract infections.J Antimicrob Chemother. 1990 Nov;26 Suppl D:55-60. doi: 10.1093/jac/26.suppl_d.55. J Antimicrob Chemother. 1990. PMID: 2286591 Review.
Cited by
-
Assessment of antibiotic levels in lung tissue with erosion-controlled dosage forms.Eur J Drug Metab Pharmacokinet. 1997 Jul-Sep;22(3):237-43. doi: 10.1007/BF03189813. Eur J Drug Metab Pharmacokinet. 1997. PMID: 9358205
-
Pseudomonas aeruginosa exoproducts determine antibiotic efficacy against Staphylococcus aureus.PLoS Biol. 2017 Nov 27;15(11):e2003981. doi: 10.1371/journal.pbio.2003981. eCollection 2017 Nov. PLoS Biol. 2017. PMID: 29176757 Free PMC article.
-
The application of in silico experimental model in the assessment of ciprofloxacin and levofloxacin interaction with main SARS-CoV-2 targets: S-, E- and TMPRSS2 proteins, RNA-dependent RNA polymerase and papain-like protease (PLpro)-preliminary molecular docking analysis.Pharmacol Rep. 2021 Dec;73(6):1765-1780. doi: 10.1007/s43440-021-00282-8. Epub 2021 May 30. Pharmacol Rep. 2021. PMID: 34052981 Free PMC article.
-
Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis.Pharmacol Rep. 2020 Dec;72(6):1553-1561. doi: 10.1007/s43440-020-00169-0. Epub 2020 Oct 15. Pharmacol Rep. 2020. PMID: 33063271 Free PMC article.
-
Ciprofloxacin is actively transported across bronchial lung epithelial cells using a Calu-3 air interface cell model.Antimicrob Agents Chemother. 2013 Jun;57(6):2535-40. doi: 10.1128/AAC.00306-13. Epub 2013 Mar 18. Antimicrob Agents Chemother. 2013. PMID: 23507281 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources